Sun completes Jack Howe drilling

THE ROADHOUSE BOWSER: Sun Resources (ASX: SUR) has completed drilling and casing operations at the Jack Howe #1H well location within the company’s Normangee oil project.

The company said the results of the analysis of the conventional core recovered from the Lower Woodbine in the Jack Howe #1H vertical pilot well are now available and have been integrated with the wireline logs to identify the potential oil pay in the well.

A total of approximately 250 feet (75 metres) of oil pay is interpreted from the wireline logs, with the core analysis data now integrated.

Sun indicated this thickness of oil pay is in line with its pre-drill expectations and confirms the potential for Lower Woodbine oil pay across the company’s Southern Woodbine leases.

“This pay interval is the zone which was the target for the Jack Howe #1H lateral and the pay potential has been confirmed by the strong oil and gas shows during drilling,” Sun Resources said in its ASX announcement.

“Strong oil and gas shows continued while drilling the horizontal section and the shows strengthened toward the end of the well bore, with a total of approximately 6,100 feet of lateral section drilled.

“The sub-surface technical data and analysis will form the basis of an independent reserve and resources report that will be initiated shortly and prepared over coming weeks.”

Sun indicated it will now integrate the data acquired while drilling, plus the core and log analysis to build a model for the design of the hydraulic fracture program for the well.

Sun is currently targeting commencing the multi-stage fraccing operation in October 2014.

Email: admin@sunres.com.au

Website: www.sunres.com.au

pSivida receives FDA approval for ILUVIEN

THE ROADHOUSE PHARMACY: pSivida Corp. (ASX: PVA) announced the United States Food and Drug Administration (FDA) has approved the company’s ILUVIEN® for the treatment of diabetic macular edema (DME).

pSivida specialises in the development of sustained release, drug delivery products for treating eye diseases.

The treatment has been indicated for patients who have been previously treated with a course of corticosteroids and did not have a clinical rise in intraocular pressure (IOP).

pSivida claimed a single injection of the ILUVIEN micro-insert provides sustained treatment of DME for 36 months.

Approximately 560,000 people in the US are estimated to have clinical DME, the most frequent cause of vision loss in individuals with diabetes and the leading cause of blindness in young and middle-aged adults in developed countries.

pSivida anticipates ILUVIEN to be commercially available in the US in early 2015.

Achieving FDA approval of ILUVIEN entitles pSivida to a $25 million milestone from its licensee Alimera Sciences.

The company will also be entitled to 20 per cent of the net profits from sales of ILUVIEN in the US.

“FDA approval of ILUVIEN, our third FDA-approved product for retinal disease, provides an important treatment option for DME patients in the US, the majority of whose DME, despite anti-VEGF intra-ocular injections as frequently as monthly, is not optimally managed,” pSivida president and chief executive officer Dr Paul Ashton said in the company’s announcement to the Australian Securities Exchange.

“ILUVIEN’s clinical trials showed that ILUVIEN can actually reverse vision loss in many DME patients.

“Another advantage of ILUVIEN over existing therapies is that a single injection provides sustained therapy for three years.

“The $25 million milestone will help finance our ongoing product development program, including Medidur™ for posterior uveitis and Tethadur™ for the sustained delivery of biologics.”

pSivida is independently developing Medidur, an injectable, sustained release micro-insert of the same design and delivering the same drug as ILUVIEN, for the treatment of chronic posterior uveitis, the third largest cause of blindness in the US.

The company plans to seek FDA approval of this product on the basis of its ongoing single Phase III clinical trial.

Enrollment of this study is expected to be completed by the end of the first quarter of calendar 2015.

ILUVIEN is already commercially available in the United Kingdom and Germany, and has received or is pending marketing approval in seventeen other EU countries, for the treatment of patients with the chronic DME insufficiently responsive to available therapies.

“We are very pleased that the FDA’s approval of ILUVIEN is not limited, as in the EU, to the subset of patients with chronic DME, patients who have failed other therapies, or patients who have had cataract surgery,” Dr Ashton continued.

pSivida explained ILUVIEN is an injectable micro-insert that provides sustained treatment through continuous delivery of a submicrogram dose of the corticosteroid fluocinolone acetonide for 36 months.

Current standard-of-care therapy requires anti-VEGF injections into the eye as frequently as monthly, and studies show that over 50 percent of patients are not optimally managed with this treatment.

pSivida  said the FDA approval was based on clinical trial data that showed that at month 24, 28.7 percent of patients receiving ILUVIEN experienced an improvement from baseline in their best corrected visual acuity on the Early Treatment Diabetic Retinopathy Study (ETDRS) eye chart of 15 letters or more.

This improvement in vision was maintained through 36 months, the end of the trials.

Website: www.psivida.com

Viralytics reports positive data from Phase 2 Trial of CAVATAK

THE ROADHOUSE PHARMACY: Viralytics Limited (ASX: VLA) announced positive results from the company’s US Phase 2 CALM trial of CAVATAK™ in late-stage melanoma at the European Society of Medical Oncology (ESMO) 2014 Congress in Madrid.

Viralytics described CAVATAK as a novel cancer immunotherapy based on a proprietary cold virus that has been shown to preferentially infect and attack cancer cells.

To date, 22 of the 57 (38.6 per cent) patients have achieved the immune‐related Progression‐Free Surviva (irPFS) endpoint, exceeding the initial target of 18.5 per cent, or 10 of 54 evaluable patients reporting irPFS at six months after the first dose of CAVATAK.

Investigators also reported an overall response rate in 16 of 57 (28 per cent) patients, with an additional three patients remaining in the extension phase of the study and being monitored for the development of an overall response.

Viralytics claims CAVATAK continues to demonstrate activity in both injected tumours and non-injected tumours, including local and distant lymph nodes, lungs and other distant sites, suggesting an anti-tumour immune response.

The company said an interim one-year survival rate of 73 per cent (33 of 45) patients was achieved in what it descrtibed as being a challenging population with advanced, difficult-to-treat disease.

CAVATAK™ treatment continues to be well tolerated in patients, with no reports of drug related serious adverse events or grade 3 or 4 adverse events, and the majority of side effects being reported as grade 1.

“These latest results further demonstrate CAVATAK’s oncolytic immunotherapeutic activity,” Viralytics chief executive officer Dr Malcolm McColl said in the company’s announcement to the Australian Securities Exchange.

“Based on CAVATAK’s outstanding performance in this trial, and with strong support from leading oncologists, we plan to aggressively pursue our clinical development program.

“The commercial opportunity for CAVATAK, either as a monotherapy or in combination with other new agents, is reinforced by these very promising outcomes.”

Website: www.viralytics.com

Gas flow from Egilabria 2 Shale Gas Well

THE ROADHOUSE BOWSER: Armour Energy (ASX: AJQ) advised the market that the company’s Egilabria 2 well has started to continuously flow gas through a test separator during the flowback recovery process.

The company said continuous flow is being observed with intermittent flaring.

However, Armour also pointed out that it has not yet measured the flow rate.

The company expects to begin flowing annulus gas through the separator in order to measure a stabilized flowrate by the end of the coming week, which it expects to further increase as more stimulation fluids are recovered.

The Egilabria 2 well is located in ATP1087 in north‐west Queensland, 300 kilometres north of Mt Isa and is 100 per cent-owned and operated by Armour.

The well is currently flowing back a mixture of stimulation fluids and gas via a downhole PCP pump through the tubing.

The start of continuous gas flow followed eight days of fluid pumping of up to 122 barrels per day.

To date 57 per cent of the original 11,400bbls stimulation fluids that were originally pumped into the well have been flowed back.

This is an increase of 12 per cent since the flowback was recommenced earlier this month.

The Lawn Shale is present in Egilabria 2 between depths of 1,583 and 1,720 metres, at 137m thick, and hosts up to 8 per cent Total Organic Content (TOC).

“During the drilling of the well, significant gas shows and flares were encountered between 425 and 1,870 metres vertical depth,” Armour Energy said in its announcement to the ASX.

“Analysis of the hydraulic stimulation undertaken in the lateral well, drilled from 1,300m depth during 2013, shows that a single zone accepted the highest volumes of larger sized proppant (used to create and hold open a conductive hydraulic fracture).

“It is therefore expected that the majority of the returning fluid and gas flow will be coming from this single zone.”

Armour’s drilling activities in 2013 included the drilling of the Egilabria 4 well, approximately 7.5kms to the north which also tested both the Lawn and the deeper, larger Riversleigh Shale Formation 250m thick.

TOC contents in the Riversleigh shale were up to 11 per cent.

Gas shows were registered against both the Lawn and Riversleigh Shales in Egilabria 4.

The company said it considers the flow test results to date from Egiliabria 2 to be very encouraging adding they substantiate the potential for economic gas flows from successfully stimulated gas wells in the Lawn Shale in the forthcoming programs.

Email: info@armourenergy.com.au

Website: www.armourenergy.com.au

APPEA unhappy with NSW gas freeze

THE ROADHOUSE BOWSER: The Australian Petroleum Production & Exploration Association (APPEA) has slammed a recent announcement from the News South Wales Government signalling plans to extend its current freeze on natural gas exploration.

The State Government announcement comes hot on the heels of a Federal Government release of its draft Energy White Paper, which highlighted the need for an urgent uplift in NSW gas production.

Needless to say that particular announcement received a much warmer welcome from APPEA, which indicated it had been backed by business and manufacturing bodies, not only in NSW, but on a national scale.

“It also appears the announcement is set to be made just days ahead of the NSW Chief Scientist’s report into the science of gas development in NSW – sending a message to industry and third parties that such policy announcements are made independent of scientific consideration,” APPEA said in its press release.

According to APPEA, NSW consumes around a quarter of the gas used in the eastern Australia gas market, yet the state supplies only about one per cent of the gas production for that market.

“The state’s 1.3 million gas customers rely on interstate producers for 95 per cent of their supply, despite the state possessing very significant reserves and experienced gas companies willing and able to produce local gas for local consumers,” APPEA said.

“NSW regulated gas prices are increasing by more than 10 per cent this year.

“New production depends upon successful exploration activity.

“And without new exploration and production in NSW, it will be very difficult to put downward pressure on NSW gas prices.”

 

 

Website: www.appea.com.au

Gavin Thomas to be remembered at Symposium Gold Awards Dinner

THE CONFERENCE CALLER: The organisers of the Gold Investment Symposium to be held in October will be awarding two new Awards to the precious metals sector: One for the mining industry, and one for the bullion industry.

The Gavin Thomas Mining Award

Many people in the precious metals industry knew long-time Kingsgate Consolidated managing director and chief executive officer, Gavin Thomas, who sadly passed away on 4 June 2014 in Sydney at the age of 63.

Thomas was a brilliant geologist and a passionate advocate of the mining industry.

He was declared a mining legend by his peers in 2005.

In honour of his life-long dedication to the industry, the Gold Investment Symposium will present the Gavin Thomas Mining Award at the forum’s annual Gold Awards dinner at the Sofitel Wentworth Hotel in Sydney on Thursday, 9th October 2014.

The award recipient will be selected by a judging panel in association with Symposium.

The recipient will be a company or individual that shows not only dedication to the industry but one who creates a strong team ethic and carries with them a unique sense of being able to get the job done while still maintaining a great joie de vivre.

The Symposium Bullion Industry Award (Affectionately known as ‘The Maggie’)

The Maggie Award will be presented to an individual or company that shows initiative and exceptional customer service in the precious metals industry.

The recipient will be a company or individual that has shown quality of service, industry knowledge, and contribution to the community and good/consistent communication.

Nominations close Tuesday, 30 September 2014

To submit a nomination for a company or individual for one of the award categories, email the Gold Investment Symposium awards coordinator michael@symposium.net.au with the following details:

Name of company or individual you wish to nominate;

Award category; and

Overview on why that company or individual deserves to be nominated with the criteria in mind (150 words max).

The Gold Investment Symposium is Australia’s most comprehensive precious metals event with economists, mining executives and market watchers all delivering the latest news and trends about the precious metals industry.

Explorers explore and miners attend mining conferences

THE CONFERENCE CALLER: An advantage to attending mining conferences, where junior exploration and mining companies are in also in attendance, is that you get to find out which ones are out on the ground doing what they do best…exploring.

A recent Explorer Quarterly Cash Update report from BDO identified 1 in 10 ASX-listed exploration companies did not carry out any exploration during the recently-completed June quarter.

“This is a very telling statistic, showing that a material portion of the ASX-listed explorers are not doing what their ‘mum and dad investors’ would be expecting them to do,” the BDO report noted.

“Investing in exploration companies has always been a more risky use of capital than investing in more stable businesses, but for companies that are not exploring at all, there is no possibility of any reward to investors for that risk.

“If this situation continues, finding investors for companies classified as ‘explorers’ will become more and more difficult.”

At the RIU Melbourne Resources Roundup there were not exploration-shy companies to be found with the exhibition booths and presentation auditorium offering investors the opportunity to mix it with the managing directors of these companies and to ask them all they questions they wanted answers to personally.

The Roadhouse managed to catch up with just a few to grab a quick snapshot of what they are currently up to.

Blackham Resources (ASX: BLK) is continuing to work towards production at the Matilda gold project, having picked up the plant and infrastructure to get into production we have moved from being a successful explorer to being a near-term producer.

“We have ticked most of the boxes we need to get into production with that plant and infrastructure and now we are focusing on getting the first five…six…seven hundred thousand ounces into the mine plan so we can turn it back on,” Blackham Resources managing director Bryan Dixon said.

“We’re doing that as quickly as we can and we are very keen to be ready for this to go into production when the world economy starts to improve.”

“The issue around the Board has been resolved – and was in pretty quick time – during that time our operational staff were still focusing on what they had to do and now the corporate staff can get back to focusing on the main game as well.”

www.blackhamresources.com.au

Pioneer Resources (ASX: PIO) has commenced aircore drilling and EM surveys at three of its projects, the Accra project for gold, the Jugla Dome project for copper-lead-zinc, and the Golden Ridge project for a nickel target.

“Everything is on track for the granting of the key Fairwater tenement in the Fraser Range and we still anticipate drilling there before Christmas,” Pioneer Resources managing director David Crook said.

“There is 5,000 metres of aircore drilling, there is another 1500m of RC drilling to immediately follow that, and we have EM surveys around the Blair mine and on a, brand new, copper-gold gossan at Jugla Dome.

“We’ve just raised $1 million and it’s time to spend it.”

www.pioneerresources.com.au

The main focus of Flinders Mines (ASX: FMS) is at the company’s Pilbara iron ore project (PIOP) where it is feverishly working to complete a feasibility study.

“We have just finished a really significant drilling program, and that has been designed to bring all of the Inferred ore into the Indicated and Measured category, from that we can develop a mining Reserve,” Flinders Mines managing director Ian Gordon said.

“So that’s been done, now we are currently working on the new Resource models, and once that’s done we can do all the mine planning

“By the end of the year we expect to complete all the mine planning and have, effectively, a mining Reserve for the project.

“We still need to get all our updated environmental approvals in place – we expect that to take until June 30 next year.

“At the same time a feasibility document will be completed in the end of the June quarter as well.

“Our project is a very good iron ore project – we would expect that we will end up with a grade of around 59 per cent iron, which will position us between the Rio Tintos of the world and Fortescue Metals Group in terms of grade.

“We think that project is going to be very attractive to partners and financiers going forward and come the middle of next year, hopefully all the bad news in the iron ore sector has washed through and we will have a stable base from which to move forward.

“We are well-funded at the moment, we have a lot of work to get on with, and probably the best thing of all is actually not to be producing right now as a junior.”

www.flindersmines.com

St George Mining (ASX: SGQ) is now at the point where it has a number of advanced nickel-sulphide targets where it is about to commence its next drilling program.

“We have just raised $1.75 million in fresh capital, so we are fully-cashed up and we are also expecting to receive a further $800,000 from a Research and Development rebate, giving us a total of $2.55 million of fresh money,” St George Mining managing director John Prineas said.

“We have actually had a few brokers congratulate us on achieving something that other junior explorers have been unable to do at the moment – in terms of our improved cash position.

“We are pleased with that, but we are even more pleased that we have a number of high-quality targets that we are about to go and drill.

“All of our targets are advanced and they just may be the ones that bring about a major discovery.”

stgeorgemining.com.au

Kibaran leads graphite charge

THE INSIDE STORY: Resource-focused investors who keep a close eye on the daily announcements from the Australian Securities Exchange (ASX) cannot have ignored how often lately the commodity graphite rates a mention.

Many pundits consider the rise in graphite’s prominence to be merely a distraction to the focus market-watchers usually save for more mainstream commodities, gold or iron ore, whose fortunes have recently suffered.

The reality though, is that graphite’s rise in providence and reputation should come as no surprise.

The European Commission included graphite amongst 14 materials it considers to be high in both economic importance and supply risk, while the British Geological Survey listed graphite as one material most likely be in short supply globally.

A number of analysts are starting to appreciate the potential of graphite, guided by data suggesting future demand is most likely to be driven by new technologies, in particular lithium-ion batteries.

The lithium-ion battery market, for which graphite demand has grown from virtually zero five years ago to almost 100,000 tonnes per annum, now represents 20 per cent of the flake market and continues to grow at 20 per cent annually.

Kibaran Resources (ASX: KNL) is positioning itself to become a major player in the emerging graphite sector.

The company’s key project is its 100 per cent-owned Epanko graphite deposit, located within the broader Mahenge project area in Tanzania.

 

The project has a total JORC Mineral Resources Estimate of 22.7 million tonnes at 9.8 per cent total graphitic carbon (TGC) for 2.22 million tonnes of contained graphite.

Kibaran recently completed a Scoping Study at Epanko based on Indicated Mineral Resources of 12.8 million tonnes at 10 per cent TGC for 1,281,200 tonnes of contained graphite.

The results from the study concluded Epanko to be an economically robust graphite deposit capable of producing premium quality large flake graphite with no industrial limitations boasting an NPV of US$213 million with plenty of upside through both resource and planned production expansion.

A key to the project is the quality of the graphite concentrate – testwork indicates the production of low contaminant, ultra-high purity (99.98 per cent) large flake graphite suitable for all applications, including the production of the value added expanded and spherical forms, which should command a premium price.

To put this into perspective it is worth noting China, India and Canada are currently responsible for most of the world’s graphite mining and processing, with China producing the lion’s share of between 70 to 80 per cent; however China’s production comprises 70 per cent amorphous and lower-value, smaller flake graphite.

Having recently completed a Scoping Study, activities are now concentrated on moving to feasibility and then construction in early 2016.

Kibaran recently appointed GR Engineering Services to undertake a feasibility and project evaluation study.

“Our main focus, at present, is the Epanko deposit at the Mahenge project,” Kibaran Resources executive director Andrew Spinks told The Resources Roadhouse.

“The appointment of GR Engineering is important as it is a highly-reputable and recognised successful engineering firm with a significant track record of building mines in Africa.

“We have signed them up to do the Feasibility Study and, ideally, they will build the plants at Epanko and at Merelani and carry out all expansion works to come.

“Our strategy is to become the largest producer of graphite in Tanzania and be able to increase production when demand increases.

“We are now finalising the schedule for the Feasibility Study.

“It is likely we will have the mining lease for Epanko finalised in March 2015 and that should concur with the Feasibility Study.

“We are anticipating production at Epanko by early 2016, which is only 18 months away.”

Kibaran signed a binding off-take agreement in 2013 with a European graphite trader for Epanko graphite sales.

The deal meant Kibaran became the first ASX-listed company to sign a graphite off-take and the first company globally to sign a binding off-take for the European graphite market.

As things currently stand, the company remains the only one of its peers with such a deal in place.

“The validation of the potential of the Epanko graphite project is confirmed by having a binding offtake agreement in place,” Spinks said.

“Many of our peers proclaim to have Memorandums of Understanding in place for hundreds of thousands of tonnes – we have an actual binding offtake agreement.

“Our test work during the recent Scoping Study has shown – through flake size distribution and high-purity – that there is absolutely no limitation in our application, or concern regarding our product.

“That is supported by the binding offtake agreement.”

The company’s second project, Merelani-Arusha, is located adjacent to the previous producing Merelani graphite mine

Kibaran is currently in negotiation with the owners of the mine, TanzaniteOne Mining Limited, which is a wholly-owned subsidiary of AIM-listed Richland Resources and Tanzania’s State Mining Corporation (STAMICO) via their STAMICO-TML Joint Venture, with a view to combine the relevant companies’ assets by way of a JV and restarting graphite production.

Having one offtake agreement in place at Epanko, with a second likely to be struck at Merelani, places Kibaran in good stead, especially in a sector such as the industrial minerals markets.

“It is a challenging sector and it is not just about tonnes and grades – there is a lot more depth to it than that,” Spinks explained.

“We are looking – in enormous detail – at why we have an offtake agreement and nobody else has and we believe it comes down to a number of factors.

“One significant aspect is our flake size distribution – 50 per cent of our distribution is greater than 180 microns, but we also have very low fine material with 15 per cent being less than 75 microns.

“That makes us commercially viable and designates our product as being very much highly in demand.”

Kibaran is highly-motivated to bring Epanko through to production as soon as possible and it has the Board structure to attain that goal.

Spinks has had a 13 year association with Africa, during which time he co-founded Tanzgraphite Pty Ltd.

Non-executive chairman John Park was founder and executive director of TSX-listed SAMAX Gold, which developed and operated the Merelani graphite mine, which remains the largest historical producer of graphite in East Africa.

The company’s other executive director, Grant Pierce has held a number of management roles in Africa including time with Perseus Mining, Resolute Mining, Africo Resources, and with Barrick Gold in Tanzania.

“We have all the right ingredients in our view in terms of the management of the company,’ Spinks said.

“We recently restructured the Board and we now consider we really have the capacity to deliver the objective to become a major graphite producer with the management box expertly ticked.”

Kibaran Resources recently reached an agreement with the CSIRO through its part-owned subsidiary 3D Graphtech Industries to investigate research opportunities in the application of graphite and graphene inks in 3D printing and fused filament fabrication.

“We’ve just engaged with the CSIRO – and it is absolutely mind-boggling what research is being done in the emerging field of 3D printing,” Spinks said.

“We are focused on becoming a graphite producer, however we can’t overlook the possibility of becoming involved in some of these other aspects of the industry.”

Kibaran Resources Limited (ASX: KNL)
…The Short Story

HEAD OFFICE
388 Hay Street
Subiaco WA 6008

Ph: + 61 8 6380 1003
Fax: +61 8 6380 1026

Email: info@kibaranresources.com
Website: www.kibaranresources.com.au

DIRECTORS
John Park, Andrew Spinks, Grant Pierce

MAJOR SHAREHOLDERS
Strategic Resource Management     4.67%
UBS Nominees                4.19%
GP Securities                3.27%

SHARES ON ISSUE
120.3 million

MARKET CAPITALISATION

Approx. $33.7 million (at 25/9/14)

Five good years plus five bad years equals one good decade

THE CONFERENCE CALLER: Opening the RIU Melbourne Resources Roundup Patersons Securities resource analyst Jason Chesters couldn’t have summed up the resource industry’s last decade any more succinctly.

“As far as the past decade in concerned, resources have performed phenomenally well,” he told a packed first day audience.

“Probably more in the first half of the decade than in the second part, but that was primarily driven by the rise of China and the demand it created for commodities.”

In other words – the last ten years have been great, however they could have been really great if it weren’t for how dire the last five have been.

Taking a look at how commodities have performed over the past decade – first up gold and silver, Chesters suggested former positive attributes that had driven the rise in the gold price had faded.

Silver, he noted broke its traditional correlation with gold around 2011, but had reverted to type in recent times.

Palladium he noted had separated from platinum’s performance with one reason being a disparity in demand for use in auto catalytic converters in gasoline vs. diesel vehicles.

On the base metal stage he described the performances of copper, tin, lead and zinc to have been much the same over the past decade with China directing the action.

Supply restrictions, he said, benefitted each commodity at various times during the period.

Nickel and aluminium, being dogged by excess supply capacity and large stockpiles, didn’t enjoy the past decades as much as, although nickel has recently recovered strongly as a result of the Indonesian unprocessed ore ban and potential emulation by the Philippines.

Chesters then turned his attention to what he considered to be the resource equity drivers over the past year.

Iron ore exposure dominates the ASX200 Materials Index, mostly through the dominance of industry heavyweights BHP Billiton (ASX: BHP) and Rio Tinto (ASX: RIO) and to a lesser extent Fortescue Metals Group (ASX: FMG), BC Iron (ASX: BCI), and Atlas Iron (ASX: AGO).

“It [iron ore] is a dominant feature of the Materials Index,” Chesters said.

“So where goes the iron ore price – so goes the Materials Index, to a large extent.”

Chesters explained the sector is going through a phase of introspection at present, especially in terms of cost reduction, capital preservation, which has made it difficult for new projects to justify their allure to the current market, which remains attracted by yield and cash flow.

“Gold has effectively lost its investor appeal, ETFs have been selling up gold,” he said.

“With iron ore we saw substantial supply increases – driven largely by the boom in margins through the high iron ore price…but that has now started to impact at the very point that we have seen China’s growth start to dwindle, and we have seen what has happened to the iron ore price…at just under $80 per tonne.”

 

Source: Patersons Securities

 

Chesters has an optimistic view of what we can expect to see from the market as we move forward.

He suggested we can look forward to improving global growth despite a marginal slowdown in Chinese growth, which should be supportive of current commodity prices in general.

“We still expect improved growth from the global economy over the next couple of years,” he said.

“Despite the marginal slowdown we have seen in China, we believe that general climate is positive for commodities.

“Investors should be focusing more on trying to isolate and ascertain which new applications and high-growth areas are around and what the potential impact could be on commodity demand from those new high-growth areas.”

Chesters drew the audience’s attention to the situation where the major companies are currently divesting their smaller projects to focus on key projects in order to conserve capital.

This creates opportunities for junior explorers and the private sector, while Merger & Acquisition activity is expected to increase.

Regeneus’ osteoarthritis cell therapy to launch in Singapore

THE ROADHOUSE PHARMACY: Regeneus Ltd (ASX: RGS) has announced plans to open the HiQCell Regenerative Medicine Clinic in Singapore.

The company also announced the appointment of specialist sports physician, Dr Patrick Goh, as medical director.

Regenus said, through the clinic, Dr Goh will provide patients in Singapore with access to the company’s HiQCell, a cell therapy for the treatment of osteoarthritis, with first treatments expected to commence in late 2014.

As well as assuming the role of medical director at the HiQCell Regenerative Medicine Clinic, Dr
Goh will become the initial treating medical practitioner for the HiQCell procedure.

“HiQCell provides a viable treatment option for mid-stage, age or impact related osteoarthritis patients who might otherwise face ongoing debilitating pain, loss of function, inability to play sport and reduced quality of life,” Dr Goh said in Regenus’ announcement to the Australian Securities Exchange.

“I am very pleased to be able to offer this treatment to my patients.”

The HiQCell Regenerative Medicine Clinic will be located at the Camden Medical Centre in
Singapore’s premier medical services district on Orchard Road where a new state of the art cell-processing laboratory has been established.

Regenus said Singapore provides a natural first overseas market for its HiQCell therapy saying the country is recognised as a leading edge medical services hub for both local and international patient treatments.

Regenus explained the HiQCell treatment involves harvesting a small amount of a patient’s own stem cells from their adipose (fat) tissue and after separating and concentrating the regenerative cells these are re-injected in osteoarthritic-affected joints such as knees, hips and ankles.

The company claims the HiQCell treatment aims to reduce inflammation and repair damaged tissue is carried out under the supervision of the treating medical practitioner.

HiQCell has been used to treat more than 500 patients and over 1,000 arthritic joints.

The cell therapy procedure is supported by safety data from a randomised controlled clinical trial and long-term safety and efficacy data is tracked through Australia’s first Joint Registry for stem cell therapy.

Website: www.regeneus.com.au
               www.hiqcell.com.au